Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Watch CeriBell's latest callCeriBell (NASDAQ:CBLL) Q3 2026 Earnings Call · Replay · Nov 3Read the transcript of CeriBell (NASDAQ:CBLL) Q3 2026 Earnings CallThe original release is unavailable here.
Story so far
Earlier from CeriBell
- Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
- Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Ceribell Reports Third Quarter 2025 Financial Results
- Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025
Later from CeriBell
- Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
- Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
- Ceribell to Participate in Upcoming March Investor Conferences
- Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Follow CeriBell into a list and get an email when it puts out news.
Follow CeriBell